Adherence to Non-Antibiotic Prophylactic Regimens in Women with Recurrent Urinary Tract Infections
International Urogynecology Journal · 2024
DOI: 10.1007/s00192-024-05928-8 ↗At a glance
Journal article in International Urogynecology Journal, 2024. Written by Sarah Ashmore and 6 co-authors. Institution: Section of Urogynecology and Reconstructive Pelvic Surgery, University of Chicago, Chicago, IL, USA. sleilaniashmore@gmail.com. Major MEDLINE topics: Urinary Tract Infections, Mannose, Estrogens, Secondary Prevention. Cited 3 times so far (Crossref); 29 references.
Abstract (original language)
INTRODUCTION AND HYPOTHESIS: Non-antibiotic regimens such as methenamine hippurate, D-mannose, and vaginal estrogen are often prescribed as prevention for recurrent urinary tract infections (rUTIs). The objective of our study was to describe adherence rates in women prescribed non-antibiotic prophylaxis for rUTI and to explore factors associated with adherence. METHODS: This was an ambispective cohort study describing and comparing adherence to non-antibiotic prophylactic regimens for rUTIs. Adult women who sought care from a Urogynecology clinic at a tertiary care center for rUTIs or frequent UTIs between January 2020 and December 2021 were included if they were prescribed a non-antibiotic prophylactic regimen. The Medication Adherence Questionnaire (MAQ) was administered to all eligible patients prospectively and then their charts were reviewed retrospectively for demographic and clinical factors. A score of 0 on the MAQ defined medication adherence. Any score ≥ 1 defined medication non-adherence. RESULTS: A total of 90 patients met the inclusion criteria and completed the MAQ, with 33 (37%) in the adherent group and 57 (63%) in the non-adherent group. Mean age was 64.7 (± 14.7) years. Vaginal estrogen (81.1%) was the most commonly prescribed prophylactic regimen, followed by methenamine hippurate (26.7%). 73.3% of patients met criteria for rUTI at the index visit as per the American Urogynecologic Society best-practice statement. No demographic or clinical factors were associated with adherence to non-antibiotic prophylactic regimens. CONCLUSIONS: Non-antibiotic prophylactic rUTI regimens are commonly prescribed; however, adherence remains low at 37%. There were no predictors associated with patient compliance. Clinicians should therefore inquire about adherence prior to escalating treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Section of Urogynecology and Reconstructive Pelvic Surgery, University of Chicago, Chicago, IL, USA. sleilaniashmore@gmail.com.
- Division of Female Pelvic Medicine and Reconstructive Surgery, Northwestern Medicine, Chicago, IL, USA.
- Division of Obstetrics and Gynecology, Northwestern Medicine, Chicago, IL, USA.
- Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Urogynecology and Reconstructive Pelvic Surgery, OB/GYN and Women's Institute, Cleveland Clinic, Cleveland, OH, USA.
ORCID profiles: Sarah Ashmore
Cite
APA
Ashmore, S., Geynisman-Tan, J., Ehimiaghe, E., Cheeks, M., Arteaga, R., Sarkar, P., & Das, D. (2024). Adherence to Non-Antibiotic Prophylactic Regimens in Women with Recurrent Urinary Tract Infections. International Urogynecology Journal. https://doi.org/10.1007/s00192-024-05928-8
Vancouver
Ashmore S, Geynisman-Tan J, Ehimiaghe E, Cheeks M, Arteaga R, Sarkar P, et al. Adherence to Non-Antibiotic Prophylactic Regimens in Women with Recurrent Urinary Tract Infections. International Urogynecology Journal. 2024. doi:10.1007/s00192-024-05928-8
BibTeX
@article{Ashmore2024,
author = {Ashmore, Sarah and Geynisman-Tan, Julia and Ehimiaghe, Eseohi and Cheeks, Morgan and Arteaga, Rebecca and Sarkar, Prottusha and Das, Deepanjana},
title = {Adherence to Non-Antibiotic Prophylactic Regimens in Women with Recurrent Urinary Tract Infections},
journal = {International Urogynecology Journal},
year = {2024},
doi = {10.1007/s00192-024-05928-8}
}
EUVIMED